EP Patent

EP2366702A1 — New oxadiazole derivatives

Assigned to Almirall SA · Expires 2011-09-21 · 15y expired

What this patent protects

The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or N-oxide thereof: and its use in the treatment of diseases which are susceptible to improvement by sphingosine-1-phosphate (S1P1) receptor agonists.

USPTO Abstract

The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or N-oxide thereof: and its use in the treatment of diseases which are susceptible to improvement by sphingosine-1-phosphate (S1P1) receptor agonists.

Drugs covered by this patent

Patent Metadata

Patent number: EP2366702A1
Jurisdiction: EP
Classification: —
Expires: 2011-09-21
Drug substance claim: No
Drug product claim: No
Assignee: Almirall SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.